AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
All Articles
HER2-Directed Therapy Is Redefining Frontline Treatment for Gastroesophageal Cancer
By Manik Amin, MD
Treatment selection for metastatic gastroesophageal adenocarcinoma now proceeds through a structured biomarker sequence.
HER2-Directed Therapy Is Redefining Frontline Treatment for Gastroesophageal Cancer
By Manik Amin, MD
Treatment selection for metastatic gastroesophageal adenocarcinoma now proceeds through a structured biomarker sequence.
HER2-Directed Therapy Is Redefining Frontline Treatment for Gastroesophageal Cancer
By Manik Amin, MD
Treatment selection for metastatic gastroesophageal adenocarcinoma now proceeds through a structured biomarker sequence.
Using MRD Testing to Decide When Multiple Myeloma Maintenance Can Stop
By Abdullah Mohammad Khan, MBBS
Indefinite lenalidomide maintenance after transplant has been standard practice in multiple myeloma for years, largely on the strength of older trials that never directly tested whether stopping was safe.
Using MRD Testing to Decide When Multiple Myeloma Maintenance Can Stop
By Abdullah Mohammad Khan, MBBS
Indefinite lenalidomide maintenance after transplant has been standard practice in multiple myeloma for years, largely on the strength of older trials that never directly tested whether stopping was safe.
Using MRD Testing to Decide When Multiple Myeloma Maintenance Can Stop
By Abdullah Mohammad Khan, MBBS
Indefinite lenalidomide maintenance after transplant has been standard practice in multiple myeloma for years, largely on the strength of older trials that never directly tested whether stopping was safe.
Advanced Chondrosarcoma Finally Has Systemic Treatment Options Under Study
By Varun Monga, MBBS
Conventional chondrosarcoma has historically had no approved systemic therapy given its resistance to chemotherapy and radiation.
Advanced Chondrosarcoma Finally Has Systemic Treatment Options Under Study
By Varun Monga, MBBS
Conventional chondrosarcoma has historically had no approved systemic therapy given its resistance to chemotherapy and radiation.
Advanced Chondrosarcoma Finally Has Systemic Treatment Options Under Study
By Varun Monga, MBBS
Conventional chondrosarcoma has historically had no approved systemic therapy given its resistance to chemotherapy and radiation.
Autologous Transplant in Multiple Myeloma: Still the Standard as Quadruplet Therapy and Cellular Immunotherapy Advance
By Jason Chandler, MD
Autologous stem cell transplant has anchored newly diagnosed multiple myeloma treatment for decades, and every major guideline body still recommends it for eligible patients.
Autologous Transplant in Multiple Myeloma: Still the Standard as Quadruplet Therapy and Cellular Immunotherapy Advance
By Jason Chandler, MD
Autologous stem cell transplant has anchored newly diagnosed multiple myeloma treatment for decades, and every major guideline body still recommends it for eligible patients.
Autologous Transplant in Multiple Myeloma: Still the Standard as Quadruplet Therapy and Cellular Immunotherapy Advance
By Jason Chandler, MD
Autologous stem cell transplant has anchored newly diagnosed multiple myeloma treatment for decades, and every major guideline body still recommends it for eligible patients.
Immunotherapy Is Moving Earlier Into Head and Neck Cancer Treatment
By Hyunseok Kang, MD, MPH
Head and neck cancer treatment has historically advanced roughly once a decade, but two meaningful updates are arriving together this year
Immunotherapy Is Moving Earlier Into Head and Neck Cancer Treatment
By Hyunseok Kang, MD, MPH
Head and neck cancer treatment has historically advanced roughly once a decade, but two meaningful updates are arriving together this year
Immunotherapy Is Moving Earlier Into Head and Neck Cancer Treatment
By Hyunseok Kang, MD, MPH
Head and neck cancer treatment has historically advanced roughly once a decade, but two meaningful updates are arriving together this year
Perioperative Intensification in High-Risk Prostate Cancer: PROTEUS, TALAPRO-3, and Treatment De-Escalation
By Putao Cen, MD
Perioperative intensification is reshaping treatment for high-risk localized and metastatic castration-sensitive prostate cancer.
Perioperative Intensification in High-Risk Prostate Cancer: PROTEUS, TALAPRO-3, and Treatment De-Escalation
By Putao Cen, MD
Perioperative intensification is reshaping treatment for high-risk localized and metastatic castration-sensitive prostate cancer.
Perioperative Intensification in High-Risk Prostate Cancer: PROTEUS, TALAPRO-3, and Treatment De-Escalation
By Putao Cen, MD
Perioperative intensification is reshaping treatment for high-risk localized and metastatic castration-sensitive prostate cancer.
Overcoming Language Barriers in Cancer Care
By Kaila Johnson
Language barriers delay cancer diagnoses and lower screening rates for patients with limited English proficiency. Experts weigh in on interpreter access, cultural competence, and why closing these gaps is critical to equitable cancer care.
Overcoming Language Barriers in Cancer Care
By Kaila Johnson
Language barriers delay cancer diagnoses and lower screening rates for patients with limited English proficiency. Experts weigh in on interpreter access, cultural competence, and why closing these gaps is critical to equitable cancer care.
Overcoming Language Barriers in Cancer Care
By Kaila Johnson
Language barriers delay cancer diagnoses and lower screening rates for patients with limited English proficiency. Experts weigh in on interpreter access, cultural competence, and why closing these gaps is critical to equitable cancer care.
MDS, MECOM-Rearranged Leukemia, and BPDCN: New Data Reshaping Treatment Choices
By Cecilia Arana Yi, MD
The VERONA trial finds venetoclax adds no survival benefit in higher-risk MDS; new data illuminate outcomes in MECOM-rearranged AML and BPDCN, where transplant remains the strongest predictor of survival.
MDS, MECOM-Rearranged Leukemia, and BPDCN: New Data Reshaping Treatment Choices
By Cecilia Arana Yi, MD
The VERONA trial finds venetoclax adds no survival benefit in higher-risk MDS; new data illuminate outcomes in MECOM-rearranged AML and BPDCN, where transplant remains the strongest predictor of survival.
MDS, MECOM-Rearranged Leukemia, and BPDCN: New Data Reshaping Treatment Choices
By Cecilia Arana Yi, MD
The VERONA trial finds venetoclax adds no survival benefit in higher-risk MDS; new data illuminate outcomes in MECOM-rearranged AML and BPDCN, where transplant remains the strongest predictor of survival.
The New Frontier in Lung Cancer Therapy: Targeted Therapy, and Bispecific Antibodies
By Robert Lin, MD
Adjuvant targeted therapy already has a track record in early-stage non-small cell lung cancer (NSCLC) driven by EGFR or ALK alterations, where it has meaningfully reduced recurrence after surgery.
The New Frontier in Lung Cancer Therapy: Targeted Therapy, and Bispecific Antibodies
By Robert Lin, MD
Adjuvant targeted therapy already has a track record in early-stage non-small cell lung cancer (NSCLC) driven by EGFR or ALK alterations, where it has meaningfully reduced recurrence after surgery.
The New Frontier in Lung Cancer Therapy: Targeted Therapy, and Bispecific Antibodies
By Robert Lin, MD
Adjuvant targeted therapy already has a track record in early-stage non-small cell lung cancer (NSCLC) driven by EGFR or ALK alterations, where it has meaningfully reduced recurrence after surgery.
Resistance to KRAS Inhibitors Is Multilayered, and Lineage Plasticity Deserves More Attention
By Konstantin Dragnev, MD
Resistance to KRAS inhibitors should be understood as three distinct categories, primary/intrinsic, adaptive/non-genetic, and acquired/genetic, each with different mechanisms and different implications for how to sequence or combine therapy.
Resistance to KRAS Inhibitors Is Multilayered, and Lineage Plasticity Deserves More Attention
By Konstantin Dragnev, MD
Resistance to KRAS inhibitors should be understood as three distinct categories, primary/intrinsic, adaptive/non-genetic, and acquired/genetic, each with different mechanisms and different implications for how to sequence or combine therapy.
Resistance to KRAS Inhibitors Is Multilayered, and Lineage Plasticity Deserves More Attention
By Konstantin Dragnev, MD
Resistance to KRAS inhibitors should be understood as three distinct categories, primary/intrinsic, adaptive/non-genetic, and acquired/genetic, each with different mechanisms and different implications for how to sequence or combine therapy.